![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » ATHENAGEN ANNOUNCES PUBLICATION OF RESULTS FROM A PROOF-OF-CONCEPT TRIAL
ATHENAGEN ANNOUNCES PUBLICATION OF RESULTS FROM A PROOF-OF-CONCEPT TRIAL
June 15, 2006
Athenagen, Inc., a privately held biopharmaceutical company, reported today that its lead compound, GTS-21, a novel, orally active alpha-7 nicotinic acetylcholine (nACh) receptor agonist, demonstrated cognition enhancement activity in a proof-of-concept study in patients with schizophrenia. The study was published in the June issue of the Archives of General Psychiatry,
a peer-reviewed publication of the American Medical Association.
PR
Newswire
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct